Safe use of Dexamethasone in pediatrics: design and evaluation of a novel stable oral suspension

  1. González-García, Iris 1
  2. Santoveña-Estévez, Ana 12
  3. Teigell-Pérez, Nuria 2
  4. Fariña, José B 12
  5. Dorta-Vera, Diego 1
  6. Suárez-González, Javier 1
  1. 1 Departamento de Ingeniería Química y Tecnología Farmacéutica, Facultad de Ciencias de la Salud , Universidad de La Laguna (ULL) , Campus de Anchieta 38203 , La Laguna (Tenerife) , Spain
  2. 2 Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC) , Universidad de La Laguna (ULL) , Campus de Anchieta 38203 , La Laguna (Tenerife) , Spain
Pharmaceutical Technology in Hospital Pharmacy

ISSN: 2365-2411 2365-242X

Year of publication: 2018

Volume: 3

Issue: 2

Pages: 59-70

Type: Article

DOI: 10.1515/PTHP-2018-0003 GOOGLE SCHOLAR

More publications in: Pharmaceutical Technology in Hospital Pharmacy


Abstract Background Dexamethasone is used in pediatrics mainly for treatment of croup and bronchopulmonary dysplasia. Commercially available pediatric oral formulations include inadequate excipients for this population. When there are only commercially available oral dosage forms for adults, a formulation is prepared to reduce the dose by manipulation of authorized tablets or injectable dosage forms. This practice most of times is made without the quality and control that process requires. The aim of this study is to propose a formulation secure and suitable for pediatrics by the use of a Standard Operating Procedure that ensures its quality. Methods Design of two formulations was performed with lowest number and amount of excipients suitable for pediatrics, avoiding use of dexamethasone salts and preservatives. An accurate and precise analytical method and a methodology for analyzing uniformity of doses were developed. Physical, chemical and microbiological stability was tested. Results Stability of Dexamethasone was improved by acidification with citric/citrate buffer. Proposed suspension complies with quality criteria required for an oral non-sterile formulation using Dexamethasone as active pharmaceutical ingredient, and the minimum number and quantity of excipients suitable for pediatrics. Conclusions This formulation is physical, chemical and microbiologically stable during 15 days storage at 5 and 25 °C.

Bibliographic References

  • Epocrates. 2017. Dexamethasone. Accessed 8 January 2018.
  • Dailymed Database. 2017. Dexamethasone. Accessed 8 January 2018.
  • EMEA. 2005. Reflection paper: formulations of choice for the paediatric population. EMEA/CHMP/PEG/194810/2005.
  • EMA. 2011. Dexamethasone Alapis. EMA/795634/2011. Accessed 8 January 2018.
  • DrugBank. 2017. Dexamethasone. Accessed 8 January 2018.
  • Acofarma. 2017. Dexametasona. Accessed 8 January 2018.
  • AEMPS. 2017. Accessed 8 January 2018.
  • Drugs@FDA. 2017. Dexamethasone. Accessed 8 January 2018.
  • Binsom G, Venisse N, Bacle A, Beuzit K, Dupuis A. Preparation and physico-chemical stability of dexamethasone oral suspension. Pharm Technol Hosp Pharm 2017;2:193–201.
  • ANSM. 2018. Dexaméthasone (acétate de) Accessed 9 January 2018.
  • CIMA. 2018. Accessed 9 January 2018.
  • Drugs@FDA. 2017. Dexamethasone acetate. Accessed 9 January 2018.
  • The United States Pharmacopeial Convention, editor. Pharmaceutical compounding – nonsterile preparations. The United States Pharmacopeia 37-The National Formulary 32, USP, ed. Baltimore: 2014. 795.
  • Bell EA Dexamethasone for mild croup. Healio [Internet] 2005. Available from: Accessed 8 January 2018.
  • EMA. 2013. Guideline on pharmaceutical development of medicines for paediatric use. EMA/CHMP/QWP/805880/2012 Rev.2. Accessed 8 January 2018.
  • EMEA. 2006. Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. EMEA/CHMP/QWP/396951/2006. Accessed 8 January 2018.
  • Ernest TB, Craig J, Nunn A, Salunke S, Tuleu C, Breitkreutz J, et al. Preparation of medicines for children – A hierarchy of classification. Int J Pharm 2012;435:124–30.
  • Standing JF, Tuleu C. Paediatric formulations – getting to the heart of the problem. Int J Pharm 2005;300:56–66.
  • Sundell-Bredenberg S, Nyströn C. The possibility of achieving an interactive mixture with high dose homogeneity containing an extremely low proportion of a micronized drug. Eur J Pharm Sci 2011;12:285–95.
  • Ensom MHH, Décarie D. Stability of extemporaneously compounded Dexamethasone in glass and plastic bottles and plastic syringes. Can J Hosp Pharm 2014;67:274–79.
  • Stovel JC. Can kids be given injectable Dexamethasone orally? Medscape [Internet] 2012 [cited 2012 Feb 23]. Available from: Accessed 8 January 2018.
  • Toledo A, Amato CS, Clarke N, Reitz RE, Salo D. Injectable Dexamethasone sodium phosphate administered orally? A Pharmacokinetic analysis of a common emergency department practice. J Pediatr Pharmacol Ther 2015;20:105–11.
  • European Pharmacopoeia 9.0th edition. 2.9.27.Uniformity of mass of delivered doses from multidose containers. Accessed 15 February 2018.
  • Chou JW-L, Decarie D, Dumont RJ, Ensom MHH. Stability of Dexamethasone in extemporaneously prepared oral suspensions. J Can Pharm Hosp 2001;54:97–103.
  • Atienza M, Martínez J, Álvarez C. Formulación en farmacia pediátrica. 4th ed. Madrid: AMV; 2011.
  • Forteza M, Galán E, Cornejo J. Interaction of Dexamethasone and montmorillonite – adsorption-degradation process. Appl Clay Sci 1988;4:437–48.
  • USP 30 NF 25. Syrup. The United States Pharmacopeial Convention (Ed.). Baltimore: Port City Press. 2006:1233–34.
  • Nováková L, Matysová L, Solich P. Advantages of application of UPLC in pharmaceutical analysis. Talanta. 2006;68:908–18.
  • ICH. 2005. Validation of analytical procedures: text and methodology. Q2(R1). Accessed 8 January 2018.
  • Wening K, Breitkreutz J. Oral drug delivery in personalized medicine: unmet needs and novel approaches. Int J Pharm 2011;404:1–9.
  • ICH. 2003. Stability testing of new drug substances and products. Q1A R2. Accessed 8 January 2018.
  • ICH. 1998. Photostability Testing of New Active Substances and Medicinal Products. Q1B. Accessed 8 January 2018.
  • Santoveña A, Suárez-González J, Martín-Rodríguez C, Fariña JB. Formulation design of oral pediatric Acetazolamide suspensión: dose uniformity and physico-chemical stability study. Pharm Dev Technol 2017;22:191–97.
  • European Pharmacopoeia 8.0th edition. 2.6.12.Microbiological examination of non-sterile products: microbial enumeration test. Accessed 16 February 2018.
  • The United States Pharmacopeial Convention, editor. Microbial examination of nonsterile products: microbial enumeration tests. The United States Pharmacopeia 37-The National Formulary 32. USP, editors. Baltimore: 2014. 61.
  • Chen Q, Zielinski D, Jenny C, Koski A, Werst D, Nowak S. A validated, stability-indicating HPLC method for the determination of dexamethasone related substances on dexamethasone-coated drug-eluting stents. J Pharm Biomed Anal 2008;48:732–38.
  • Florey K, editor. Analytical profiles of drug substances. London: Academic Press, 1973:163–97.
  • Brayfield AM. The Extra Pharmacopoeia. 28th ed. London: The Pharmaceutical Press; 1982.
  • Hansen J, Bundgaard H. Studies on the stability of corticosteroids, III. Separation and quantitation of hydrocortisone and its degradation products by high-performance liquid chromatography. Arch Pharm Chem 1980;8:91–99.
  • Santoveña A, Suárez-González J, Vera-Cabrera M, González-Martín C, Soriano M, Fariña JB. Effectiveness of anti-microbial preservation of extemporaneous diluted simple syrup vehicles for paediatrics. J Pediatr Pharmacol Ther 2018.